Active — Not RecruitingNot Applicable

Iceland Screens, Treats or Prevents Multiple Myeloma

Iceland80,761 participantsStarted 2016-09-01

Plain-language summary

This study will assess the benefits and harms of screening for monoclonal gammopathy of undetermined significance (MGUS). The overall and disease-specific mortality will be compared between screened and not screened participants. All individuals registered as inhabitants in Iceland and born in 1975 or earlier have been invited to participate. The hypothesis is that an early detection of multiple myeloma (MM), through follow-up of MGUS, will improve overall survival and decrease complications associated with diagnosis and treatment of MM.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Born 1975 or earlier * With registered address in Iceland on November 1st 2016 Exclusion Criteria: * Prior multiple myeloma * Lymphoproliferative disease * Amyloidosis * M-protein \>30 g/L or involved:uninvolved serum FLC ratio \>100 Individuals with prior history of MGUS will be offered to be randomized into either moderate or intensive clinical follow-up (arms 2 or 3).

What they're measuring

Overall survival

Timeframe: 5 years from study start.

Trial details

NCT IDNCT03327597

SponsorUniversity of Iceland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-01

View on ClinicalTrials.gov More Monoclonal Gammopathy of Undetermined Significance trials